Respiratory syncytial virus (RSV) is a common cause of acute lower respiratory infection in children and adults. While most adults who get RSV experience mild symptoms similar to the common cold, certain individuals, such as older adults and those with pre-existing conditions or weakened immune systems, are at higher risk of severe complications. Long-term effects of RSV in adults can include damage to the lungs, airways, and heart. These complications can lead to pneumonia, bronchiolitis, worsening asthma symptoms, exacerbated COPD symptoms, and severe heart symptoms.
In response to the severity of RSV infections, the U.S. Food and Drug Administration (FDA) and the Advisory Committee on Immunization Practices (ACIP) have approved two new vaccines for the prevention of RSV (Arexvy and Abrysvo) for adults aged 60 years and older. Both vaccines have shown efficacy in preventing RSV lower respiratory tract disease (RSV-LRTD). Ongoing studies are evaluating the RSV vaccine in adults aged 50 to 59 and in infants.
A poll conducted by the Global Healthy Living Foundation found that 41% of adults aged 60+ with chronic illnesses have received the RSV vaccine. Lack of doctor recommendation, unawareness, and timing issues were cited as reasons for not getting the vaccine. More than half of those who received the RSV vaccine did not experience any side effects.
As the holiday season approaches, experts are urging people to get vaccinated against respiratory viruses, including the flu, Covid-19, and RSV. Vaccines take about two weeks to provide optimal protection, so it's not too late to get vaccinated. Weekly hospitalizations for respiratory viruses are on the rise, and Covid-19 levels in wastewater are high. However, vaccination rates are low, with fewer than 2 in 5 adults and children receiving the flu vaccine this season.
